Extrait

The primary objective for the study is to evaluate the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme (300 mg on day 1, 600 mg on day 2 and 800 mg on day 3) compared to the current approved label titration (50 mg on day 1, 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, 400 mg on day 5, 600 mg on day 6 and 800 mg on day 7). The safety profile of both titration schemes will be measured with the proportion of patients who discontinue the study treatment due to adverse events (AEs) during the first week (day 1 to day 7) of treatment.

Critère d'inclusion

• Patients hospitalised with a DSM-IV diagnosis of schizophrenia showing acute agitation and psychosis

Liens

• ictrp
• euctr